Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive-interstitial lung disease.

P. Bay (Creteil, France), M. Pineton De Chambrun (Paris, France), A. Roux (Siuresnes, France), V. Bunel (Paris, France), A. Combes (Paris, France), D. Israël Biet (Paris, France), B. Zuber (Paris, France), H. Nunes (Paris, France), Y. Allenbach (Paris, France), Y. Uzunhan (Paris, France)

Source: International Congress 2022 – COVID-19 acute respiratory distress syndrome and beyond

Session: COVID-19 acute respiratory distress syndrome and beyond
Session type: Oral Presentation
Number: 2314

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Bay (Creteil, France), M. Pineton De Chambrun (Paris, France), A. Roux (Siuresnes, France), V. Bunel (Paris, France), A. Combes (Paris, France), D. Israël Biet (Paris, France), B. Zuber (Paris, France), H. Nunes (Paris, France), Y. Allenbach (Paris, France), Y. Uzunhan (Paris, France). Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive-interstitial lung disease.. 2314

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.